A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease

This study is testing a new inhaled powder medication called TQC3721 in people with moderate to severe chronic obstructive pulmonary disease (COPD) — a lung disease that makes it hard to breathe. The study aims to see how well the medication improves breathing compared to existing treatments. **You may be eligible if...** - You are between 40 and 75 years old - You have been diagnosed with stable, moderate to severe COPD based on standard breathing tests - Your breathing test shows that you have limited airflow (FEV1/FVC below 0.7, and FEV1 between 40% and 80% of predicted) - Your airways show some ability to open up after using a bronchodilator (a breathing-relief drug) - You are currently on or willing to switch to bronchodilator inhalers for COPD **You may NOT be eligible if...** - You have very severe COPD (FEV1 below 40% of predicted) - You have had a COPD flare-up or used oral steroids recently - You have significant other lung conditions (such as asthma, active tuberculosis, or lung cancer) - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.